Figure S1 from Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer

Abstract

Patients were randomized to receive one injection durvalumab 0.75 g i.v. or placebo two weeks prior to start of chemotherapy (window trial). This was followed by nab-paclitaxel 125 mg/m2 weekly for 12 weeks with durvalumab 1.5 g i.v. or placebo every 4 weeks. This was followed by epirubicin/cyclophosphamide every two weeks for four cycles with durvalumab or placebo every four weeks. After an amendment, the window phase was stopped, and all patients started with chemotherapy and durvalumab/placebo on day one. Formalin-fixed and paraffin-embedded core biopsy samples were collected prior to randomization (mandatory).